Abstract:Tetraploid (4N) cells are considered important in cancer because they can display increased tumorigenicity, resistance to conventional therapies, and are believed to be precursors to whole chromosome aneuploidy. It is therefore important to determine how tetraploid cancer cells arise, and how to target them. P53 is a tumor suppressor protein and key regulator of tetraploidy. As part of the "tetraploidy checkpoint", p53 inhibits tetraploid cell proliferation by promoting a G1-arrest in incipient tetraploid cells (referred to as a tetraploid G1 arrest). Nutlin-3a is a preclinical drug that stabilizes p53 by blocking the interaction between p53 and MDM2. In the current study, Nutlin-3a promoted a p53-dependent tetraploid G1 arrest in two diploid clones of the HCT116 colon cancer cell line. Both clones underwent endoreduplication after Nutlin removal, giving rise to stable tetraploid clones that showed increased resistance to ionizing radiation (IR) and cisplatin (CP)-induced apoptosis compared to their diploid precursors. These findings demonstrate that transient p53 activation by Nutlin can promote tetraploid cell formation from diploid precursors, and the resulting tetraploid cells are therapy (IR/CP) resistant. Importantly, the tetraploid clones selected after Nutlin treatment expressed approximately twice as much P53 and MDM2 mRNA as diploid precursors, expressed approximately twice as many p53-MDM2 protein complexes (by co-immunoprecipitation), and were more susceptible to p53-dependent apoptosis and growth arrest induced by Nutlin. Based on these findings, we propose that p53 plays novel roles in both the formation and targeting of tetraploid cells. Specifically, we propose that 1) transient p53 activation can promote a tetraploid-G1 arrest and, as a result, may inadvertently promote formation of therapy-resistant tetraploid cells, and 2) therapy-resistant tetraploid cells, by virtue of having higher P53 gene copy number and expressing twice as many p53-MDM2 complexes, are more sensitive to apoptosis and/or growth arrest by anti-cancer MDM2 antagonists (e.g. Nutlin).

Inactivation Of P53 Increases The Cytotoxicity Of Camptothecin In Human Colon Hct116 And Breast Mcf-7 Cancer Cells

Expression of mutant p53 affects cancer cell sensitivity to topotecan

Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.

Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment

Modulation of Cisplatinum Cytotoxicity by P53: Effect of P53-Mediated Apoptosis and DNA Repair

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line

Pifithrin-α Enhancing Anticancer Effect of Topotecan on P53-Expressing Cancer Cells

P53 Gene Mutations Are Associated with Decreased Sensitivity of Human Lymphoma Cells to DNA Damaging Agents.

Inhibitory Effect of Bcl-2 on P53-Mediated Transactivation Following Genotoxic Stress

Comparable radiation sensitivity in p53 wild-type and p53 deficient tumor cells associated with different cell death modalities

CHK1-Regulated S-phase Checkpoint Response Reduces Camptothecin Cytotoxity

Ku Affects The Ataxia And Rad 3-Related/Chk1-Dependent S Phase Checkpoint Response After Camptothecin Treatment

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type P53 but Not Mutant P53 to Topotecan Treatment

Effects of Wild-Type P53 Expression on the Quantity and Activity of Topoisomerase Ii Alpha and Beta in Various Human Cancer Cell Lines

53Bp1 Loss Suppresses the Radiosensitizing Effect of Icotinib Hydrochloride in Colorectal Cancer Cells

Targeting P53 for Novel Anticancer Therapy.

p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection

EFFECTS OF P53 ON GROWTH AND CYCLE RELATIVE GENES OF MCF-7 BREAST CANCER CELLS

Biological Effects of p53 Mutation W248 and H175 on MCF-7 Cells

Concentration-dependent Differential Effects of an Epothilone Analog on Cell Cycle and P53 Signaling.